Development of localized surface plasmon resonance biosensor for COVID-19 antibodies in blood

本项目旨在利用台式局部表面等离子体谐振仪(LSPR)开发一种同时检测血液中相应的免疫球蛋白抗体和免疫球蛋白M抗体的方法。与病毒蛋白或RNA的检测相比，血液抗体的检测具有检测窗口长、了解免疫应答等优点。我们将使用新冠肺炎病毒的SPAKE蛋白，将其固定在纳米金颗粒上，制成包含三个独立斑点的传感器，分别用于免疫球蛋白G、免疫球蛋白M和对照，并使用微流控系统传递样本。我们将仔细确定免疫球蛋白和免疫球蛋白M的检测下限，并在必要时探索信号放大方法。这种方法可以制成高精度的高通量检测，行业合作伙伴Nicoya Lifesciences将把这种检测商业化。该项目将增加加拿大在检测新冠肺炎感染方面的专业知识。

This project aims to use a benchtop localized surface plasmon resonance (LSPR) instrument to develop an assay for simultaneous detection of the corresponding IgG and IgM antibodies from blood. Compared to the detection of viral protein or RNA, the detection of blood antibodies has a number of advantages such as longer detection window and understanding the immune response. We will use the spike protein from the COVID-19 virus and immobilize it on gold nanoparticles to produce sensors containing three separate spots for IgG, IgM and control, respectively, and use a microfluidic system to deliver the samples. We will carefully determine the detection limit of both IgG and IgM and will explore signal amplification methods if necessary. This method can be made into a highly accurate high throughput assay, and the industry partner, Nicoya Lifesciences, will commercialize this assay. This project will increase Canada's expertise in detecting COVID-19 infection.